Orexigen Therapeutics (OREX) Tops Q1 EPS by 2c, Sales Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
May 4, 2016 4:01 PM EDTSAN DIEGO, May 4, 2016 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
"In preparation for the completion of our acquisition of U.S. rights to Contrave® (naltrexone HCl/bupropion HCl extended release), our team has made rapid progress advancing our commercial plans, including assembling talented and experienced sales and marketing leadership," said Mike Narachi, CEO of Orexigen.
Narachi continued: "We believe patients seeking medication-assisted weight loss deserve new alternatives to the treatment most commonly offered today, generic amphetamines... More
